✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Medicamen Biotech Ltd.

MEDICAMEQ

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹530 Cr.
P/E
49.51

Medicamen Biotech Ltd.

  • Medicamen Biotech
  • Prevest Denpro
  • Jenburkt Pharma
  • TJI Pharma - Small Cap

FAQs on Medicamen Biotech Ltd. Shareprice

Medicamen Biotech has given lower returns compared to its competitors.
Medicamen Biotech has grown at ~-22.81% over the last 3yrs while peers have grown at a median rate of 8.62%

Medicamen Biotech is not expensive.
Latest PE of Medicamen Biotech is 49.51, while 3 year average PE is 63.92.
Also latest EV/EBITDA of Medicamen Biotech is 35.3 while 3yr average is 36.5.

View FAQ's On Business

Growth Table

  • Medicamen Biotech Ltd.
  • Prevest Denpro
  • Jenburkt Pharma

Balance Sheet

  • Medicamen Biotech Ltd.
  • Prevest Denpro
  • Jenburkt Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Medicamen Biotech Ltd.
  • Prevest Denpro
  • Jenburkt Pharma

Cash Flow

  • Medicamen Biotech Ltd.
  • Prevest Denpro
  • Jenburkt Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Medicamen Biotech Ltd.
  • Prevest Denpro
  • Jenburkt Pharma

Quarterly Results

  • Medicamen Biotech Ltd.
  • Prevest Denpro
  • Jenburkt Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Medicamen Biotech Ltd. Financials

Balance sheet of Medicamen Biotech is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Medicamen Biotech is decreasing.
Latest net debt of Medicamen Biotech is -₹5.03 Crs as of Sep-25.
This is less than Mar-25 when it was ₹26.29 Crs.

The profit is oscillating.
The profit of Medicamen Biotech is ₹8.5 Crs for TTM, ₹6.56 Crs for Mar 2025 and ₹9.49 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Medicamen Biotech latest dividend payout ratio is 19.39% and 3yr average dividend payout ratio is 13.79%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech